AFT Pharmaceuticals (AFT Pharmaceuticals) EV-to-EBIT : 0.00 (As of Jun. 23, 2024)

View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AFT Pharmaceuticals's Enterprise Value is $0.00 Mil. AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $15.58 Mil. Therefore, AFT Pharmaceuticals's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for AFT Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

AFTPF' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.77 Med: 20.08 Max: 67.28
Current: 13.68

During the past 9 years, the highest EV-to-EBIT of AFT Pharmaceuticals was 67.28. The lowest was -27.77. And the median was 20.08.

AFTPF's EV-to-EBIT is ranked better than
63.72% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.05 vs AFTPF: 13.68

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AFT Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil. AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $15.58 Mil. AFT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

AFT Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for AFT Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals EV-to-EBIT Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EV-to-EBIT

Get a 7-Day Free Trial

18.70

49.14

19.44

21.22

13.55

AFT Pharmaceuticals Quarterly Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial												19.44	-	21.22	-	13.55

Competitive Comparison of AFT Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's EV-to-EBIT falls into.

AFT Pharmaceuticals EV-to-EBIT Calculation

AFT Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	15.578
	=	0.00

AFT Pharmaceuticals's current Enterprise Value is $0.00 Mil.
AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.58 Mil.

AFT Pharmaceuticals (OTCPK:AFTPF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AFT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	15.578	/	0
	=	%

AFT Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil.
AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.58 Mil.

AFT Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (AFT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.